Drugs / Aprutumab ixadotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02368951 | Mar 2015 → Jul 2016 | — | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aprutumab ixadotin | “Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use a novel auristatin-based payload.” PMID 31502117 ↗ Oct 2019 |
| Known as | BAY 1187982 | “Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use a novel auristatin-based payload.” PMID 31502117 ↗ Oct 2019 |
| Route | Intravenous | “administered intravenously on day 1 of every 21-day cycle” PMID 31502117 ↗ Oct 2019 |
| Target | FGFR2 | “the first antibody-drug conjugate (ADC) to target FGFR2” PMID 31502117 ↗ Oct 2019 |